Dosing of convalescent plasma and hyperimmune anti-SARS-CoV-2 1 immunoglobulins: a phase I/II dose finding study https://www.medrxiv.org/content/10.1101/2023.03.07.23286893
CleverLibre Social is an inclusive social instance for open discussion, learning, and community. All cultures welcome. Hate speech and harassment strictly forbidden.